NYU SoM IRB Newsletter (previous newsletters)
more detail-oriented than previous issues: guaranteed!
Table of Contents
Did You Know?
Did You Know?"
If you read this newsletter using Firefox, it'll look better? Because it will, you know.

From the Desk of Elan Czeisler
The IRB education team—made up of our IRB staff members—successfully completed a series of courses titled IRB 101 on August 2, 2006. We would like to thank all of you who attended. We believe one of the most important components of an effective human subjects protection program is the continuing education of its research community.
The education team meets regularly to plan the educational initiatives for both Research and IRB staff. The team, with the assistance of past program attendees, has developed a new educational series to start in the fall of 2006. The next article in this newsletter outlines the series. We would appreciate ideas you have for future sessions; please send them to irb-info@med.nyu.edu.
CITI Human Subjects & HIPPA Tutorials
New Human Subjects & HIPPA tutorial programs will be implemented on January 1, 2007. This web-based tutorial program titled the Collaborative IRB Training Initiative ("CITI") and located at https://www.citiprogram.org/default.asp will replace all of our existing tutorials.
All investigators and research team members will be required to complete CITI (regardless of the source or type of funding they have) prior to receiving approval for new and continuing research studies submitted to the IRB. This policy is effective January 1, 2007. Instructions for registration and use of the new education module will be posted in October's Newsletter.
Electronic IRB Submissions
Implementation of CITI will coincide with the development and testing of our new IRB electronic submission system. This system will allow the IRB to receive all submissions via a web browser, and should significantly enhance our ability to serve the medical research community. More information on our eForms system will be coming in newsletters to follow.

Elan Czeisler, Director
NYU School of Medicine IRB

[back to top]

IRB Education for Fall
The IRB Staff want to thank everyone who attended our recent IRB 101 series. We were very happy with the level of attendance and enthusiasm. Members of the research community who attended the sessions over the last 7 weeks were given the opportunity to provide feedback which has shaped our Fall 2006 series, and we are pleased to announce the Institutional Review Board (IRB) Educational Series—2006 Fall Session.
The sessions are divided into two tracks: (1) a general track for anyone conducting and/or managing research involving human subjects, and (2) a researcher track for investigators, residents, fellows and medical students.
Sessions will be held from September 27, 2006 through December 20, 2006, every Wednesday at 12:00 p.m. Please register early, as these sessions tend to fill up quickly.
Track: General
Ask the IRB
Session Covers: The IRB Administrative staff will be available during this 1 hour informal session to answer questions, clarify policies and discuss any other topics of interest.
If you are interested in attending this session please forward you questions or topics of interest to the IRB office at irb-info@med.nyu.edu. If your questions are not forwarded to the IRB before the session, there may not be enough time to address the question and it will be held over for the next session.
Target Audience: Anyone conducting and/or managing research involving human subjects
Dates: Wednesday - September 27, 2006, October 18, 2006 & November 15, 2006
Time: 12PM
Place: Schwartz D
Instructors: Helen Panageas & Kim Diccianni
Pre-Registration is required on line here
Mark Up your IRB Forms
Session Covers: This session will involve interactive discussion regarding the IRB forms. A form will be selected in advance for discussion at each session.
Target Audience: Anyone conducting and/or managing research involving human subjects
Dates: Wednesday - October 4, 2006 & November 8, 2006
Time: 12PM
Place: Schwartz D
Instructors: Helen Panageas & Kim Diccianni
Pre-Registration is required on line here
IRB forms will be emailed to participants in advance. All participants must (attempt to) complete the form to facilitate in-class discussion.
Elements of a Consent Form
Session Covers: The required components as per federal regulations and NYU SOM policy. Tips on how to write a consent form at an 8th grade reading level.
Target Audience: Anyone conducting and/or managing research involving human subjects
Dates: Wednesday - November 1, 2006 & December 20, 2006
Time: 12PM
Place: Schwartz D
Instructors: Helen Panageas & Germaine Cuff
Pre-Registration is required here
soothing yet meaningless illustration (you're welcome)
Track: Researcher
Does my study qualify for Exemption or Expedited review?
Session Covers: The differences between exempt and expedited federal categories. Types of studies that qualify for this type of review and what is required when submitting this type of project to the IRB
Target Audience: Researchers, residents, fellows and medical students
Dates: Wednesday - October 11, 2006 & December 6, 2006
Time: 12PM
Place: Schwartz D
Instructors: Helen Panageas & Kim Diccianni
Pre-Registration is required here
Elements of Protocol
Session Covers: Details of the IRB's required components that make up an human subject research protocol. The audience will be provided with a formula on how to write a protocol that is IRB 'approvable'
Target Audience: Researchers, residents, fellows and medical students
Dates: Wednesday - November 1, 2006 & December 13, 2006
Time: 12PM
Place: Schwartz D
Instructors: Elan Czeisler & Kim Diccianni
Pre-Registration is required here
Elements of a Consent Form
Session Covers: The required components as per federal regulations and NYU SOM policy. Tips on how to write a consent form at an 8th grade reading level.
Target Audience: Anyone conducting and/or managing research involving human subjects
Dates: Wednesday - October 25, 2006 & December 20, 2006
Time: 12PM
Place: Schwartz D
Instructors: Helen Panageas & Kim Diccianni
Pre-Registration is required here

[back to top]

Rethinking the Informed Consent Process
This article is the first in a series exploring the informed consent process with respect to human subject research. Future articles in this series will cover the requirements of the informed consent process in the US and varied approaches to informed consent process throughout the world, how the IRB can assist research teams in the development of different methods of informed consent processes for unique consent situations and cultural norms and different attitudes towards informed consent.
Cultures, religions and languages vary widely in the United States. This diversity has not, however, led to a flexible consent process that addresses the varying cultures, religions and languages found here. While other industrialized nations are working towards creating more useful informed consent approaches, the U.S., confronted with very specific federal regulations, has done little to address the diversity of its own population. The "melting-pot" of America is not well-represented in the informed consent process.
What is Informed Consent in Research?
Informed consent is defined as the process of presenting information to potential research subjects in order to enable each person to voluntarily decide whether or not to participate in a research study. The process of obtaining informed consent must comply with the requirements of 45 CFR 46.116. The documentation associated with informed consent must comply with 45 CFR 46.117, requiring that the consent process be documented with written consent forms approved by the IRB. The written presentation of information is used to document the basis for consent and for the subjects' future reference1.
A Basis for Consent
Consider the following question: How does the written consent document act as "A Basis for Consent":
  1. It is proof that the requirements were completed as set forth in 45 CFR 46.116
  2. It is evidence that the subjects were told about the study's purpose, duration, experimental procedures, alternatives, risks, and benefits in "lay language" (i.e. understandable to the people being asked to participate)
  3. It is the documentation for liability purposes and assures authorities that proper signatures were received prior to the commencement of experimental procedures
  4. It is assurance that protects and assists subjects of the many different cultural, educational, and socioeconomic backgrounds and helps subjects decide whether or not to volunteer for research
  5. None of the above
  6. All of the above
The answer is: none of the above. None of the answers above necessarily ensure that a consent document has acted as the basis of consent. Neither do any of the answers demonstrate that adequate consent has been obtained from a given subject.
Can We Guarantee Adequate Consent has Been Achieved?
soothing yet meaningless illustration (you're welcome)
First, it may be helpful to review the federal regulations on Informed Consent in research involving human subjects. The federal regulations at 45 CFR 46.116 require that specific information be given to all subjects in a written document in order to ensure that the subjects are presented with the appropriate details regarding the study. Information that must be provided includes: (1) a statement that the project is research; (2) requirements of the subject; (3) the benefits the subject will receive; (4) any foreseeable risks to the subject; (5) alternatives to participation in the study; (6) a statement describing the extent to which the subject's Protected Health Information ("PHI") will be protected; (7) a statement discussing whether or not compensation will be provided to the subject for a research related injury; (8) contact information for questions relating to the study; (9) a statement of the rights of a research subject; (10) a statement that participation is voluntary and that the subject may withdraw at any time, and (11) any additional requirements as they apply to the study. These additional requirements may include: (a) a statement describing the termination of a subject's participation; (b) a statement describing any additional costs the subject may receive as a result of participation in the study; (c) a statement describing the consequences of withdrawal from the study and how a subject should withdraw from the study; (d) a statement describing when and how significant new findings will be conveyed to the subject, and (e) the approximate number of subjects involved in the study. Again, remember the required information must be documented by the use of a written informed consent form approved by the IRB and the document must be signed by the subject.
Federal regulations leave little flexibility when it comes to consenting subjects—and place a great deal of emphasis on the consent document. While guidance from the Office of Human Research Protection (OHRP) states that informed consent is a process (not just a form), and should be designed to educate the subject population in terms that they can understand, the guidance states that information must be presented in a written format2. The guidance is ambiguous in terms of fostering real understanding between the researcher and their subject, but the regulations are quite rigorous in terms of what minimum consent materials must be in place.
Following the federally mandated written requirements raises the concern that a large segment of the population may not receive adequate information with respect to the research being undertaken. Perhaps the narrow federal regulations and vague OHRP guidance is the reason that researchers struggle to write meaningful informed consent for subjects—sometimes resulting in poor study enrollment, limited comprehension and a distrust of research.
Alternative approaches to presenting and/or documenting informed consent may be necessary in certain types of research. However, neither the regulations nor guidance issued by the federal provide any direction in this area. To remain in compliance with the regulations—including proper written documentation—and deliver adequate informed consent so that subjects know:
  1. they are in a research study
  2. understand all the risks and potential benefits
  3. understand the alternatives
  4. etc
is often a struggle, and does not necessarily guarantee adequate consent.
Can the 'Basis of Informed Consent' be Served by Other Means of Documentation?
There is some confusion in the research community—including IRBs—over the various aspects of what constitutes informed consent. Some believe that informed consent is complete when the subject reads the document and signs it. Some believe that the discussion that takes place between the researcher and subject is the most important element, and ensures the subject has been properly enrolled. Others place priority on the written contents of informed consent document.
Ideally, the basis of informed consent is achieved through a well written consent document approved by an IRB in language easily understood by the subject along with discussion with the subject regarding the research, presentation of the document to the subject, allowing the subject the opportunity to ask questions, allowing the subjects to take the document home (where feasible) for discussion with family and caregivers, and having the subject sign the consent form with the Investigator present. Information should be presented throughout the research study to facilitate a dialogue with the subject and allow them to ask questions. Finally, results of the research should be relayed to the subjects. Educating subjects, minimizing their fear and uncertainty: this is the goal of the basic informed consent process.
The typical informed consent process starts with a discussion between the research subject and the research team. The subject is given a informed consent form and the subject is asked to sign the consent form as proof of the discussion and their agreement to participate in research. No matter how well written your form is, you should question your subject's comprehension:
  • has the subject really understood what is to be done?
  • does the subject really know they are in research study?
  • did the documentation serve as the basis of this process, or did the research team and the formal and informal discussions that took place with the subject serve as the basis of informed consent?
Research on the consent process—including how it fairs in the medical research arena—is being conducted throughout the world. Consent procedures and documentation that differ from the approached outlined in the U.S. regulations are being explored outside the US. These 'outside the box' studies are finding better methodologies which may enhance the standard consent process.
Thinking "Outside the Box"
soothing yet meaningless illustration (you're welcome)
A recent study evaluated different interventions used to improve research participants understanding of information disclosed in the informed consent process. Studies published during 2004-2006 were evaluated and the researchers concluded that efforts to improve understanding through the use of multimedia and enhanced consent forms have had limited success. Having the research team or a neutral educator spend more time talking one-on-one to study participants appears to be the most effective available way of improving research participants' understanding3.
Another recent study assessed a continuous consent process in which information is given to research participants at different stages in a trial. The continuous consent approach to obtaining informed consent gives subjects information at more than one point in the trial so that they will assimilate the information better. The continuous consent process was used in the Total Body Hypothermia (TOBY) trial, a randomized controlled trial (RCT), investigating the use of whole-body cooling for neonates with evidence of perinatal asphyxia. The process was divided into three main elements.
  • Element 1: If the baby is born in a non-cooling centre, the parents are given preliminary information about the trial, including a preliminary information leaflet, while the baby is assessed for eligibility. (If deemed appropriate, the leaflet may also be given to parents of babies born in a cooling centre, or preliminary information may be offered more informally.)
  • Element 2: If the baby is eligible, a second, more comprehensive, information leaflet is given to the parents and further discussion takes place. At this point, parents are asked for their written consent and randomized.
  • Element 3: During the intervention period, the consultant neonatologist meets the parents to ensure that they understand the trial procedures and wish to continue participating in the trial. It is made clear that the parents remain free to withdraw their baby from the trial.
The study found an improvement in consent validity at the point of signature to that at the post-signature phase for each parent. At the point of signature (element 2), 22 of 30 (73%) mothers and 8 of 27 (30%) fathers had major or serious problems with the validity of their consent. In the post-signature phase, (element 3), there was a drop in serious problems with the validity of consent to 7 of 29 (24%) mothers and 4 of 26(15%) fathers4.
A study involving HIV-seronegative volunteers recruited into a longitudinal cohort to study rates of high-risk sexual behavior and incidence of HIV-1 infection gave all volunteers information about the consent form during two educational sessions. In the first session, groups of 5 to 10 volunteers viewed an educational video on the essential elements of the consent form. In the second, the volunteers met one-on-one with a social worker. Volunteers' comprehension was then evaluated orally by 16 true-false questions and 4 open-ended questions. Volunteers who failed the first evaluation received additional education and had a second evaluation.
Of two hundred fifty volunteers that received education, 186 (74%) passed the first evaluation. Of the 64 who failed, 47 returned for a repeat one-on-one education session and a second evaluation. Among these 47, 39 (83%) passed, and 8 (7%) failed the second evaluation. In total, 225 (90%) of 250 individuals passed either the first or second evaluation and were eligible to enroll in the study. The researchers concluded that informed consent using an educational video ensures good comprehension with additional educational sessions necessary for some subjects with lower educational level5.
Research is being conducted on varying approaches to informed consent processes and data is emerging to support the notion that different approaches not only improve enrollment but increase comprehension.
In the next IRB Newsletter we will discuss how the IRB can assist research teams in the development of different methods of informed consent processes for unique research consent situations.

References
  1. Office of Human Research Protection. Tips on Informed Consent updated June 23, 2000 http://www.hhs.gov.ohrp/humansubjects/guidance/ictips.html.
  2. Office of Human Research Protection. Tips on Informed Consent updated June 23, 2000 http://www.hhs.gov.ohrp/humansubjects/guidance/ictips.html.
  3. Flory J, Emabuel E. Interventions to improve research participants' understanding in informed consent for research: a systematic review. JAMA 2004; 292(13):1593-601
  4. Allmark P, Mason S. Improving the quality of consent to randomized controlled trials by using continuous consent and clinician training in the consent process. Journal of Medical Ethics 2006;32:439-443
  5. Joseph P, Schackman BR, Horwitz R. The Use of an Educational Video During Informed Consent in an HIV Clinical Trial in Haiti. Journal of Acquired Immune Deficiency Syndrome 2006;42(5):588-591

[back to top]
How Are We Doing?
Do you know about our program the NYU SOM IRB Feedback Project? Take some time and (as the title says) to let us know how we're doing! The information you provide is completely confidential.
Your submission is reviewed by a non-project reviewing administrative staff member, and kept strictly anonymous. You will not be identified in any way to any of the IRB staff. Please send us ideas on what services we could provide to promote faster review, enhance protection of human subjects, make your interactions with the IRB better, etc.
Let us know by e-mailing the IRB Feedback Project at IRB-FEEDBACK@med.nyu.edu. Look for these stickers and posters around the institution:

How Are We Doing?

[back to top]
Questions & Answers
soothing yet meaningless illustration (you're welcome)
A pre-review was completed on my project. Modifications and changes were requested by the reviewer. Do I need to re-submit the whole packet or just the documents that need to be revised?
You only need to submit those documents requiring revisions. For example, if no changes were requested to your protocol, then you do not need to re-submit the protocol. Please be sure to submit a receipt with your submission and the number of copies required for the revised document(s).
What is the next due date for IRB submissions?
The due dates and Board meeting schedules are found on our website here: http://www.med.nyu.edu/irb/schedule/index.html
My NIH K Award grant has been reviewed and approved by the IRB. I am now ready to start the research. Do I now have to send in the human subjects research projects contained within the grant separately for review by the IRB?
Yes. Only your grant application was reviewed and approved. The separate human research projects for the specific aims of the grant now have to be reviewed and approved individually to ensure that your consent practices and other proposed methods are within compliance. A separate review needs to be submitted for each study, and will also need to be submitted for annual review if it does not qualify as exempt. Attach your original grant approval letter to each study to show that the submission is an off-shoot of the original review./div>
How many copies do I submit with my study's initial IRB submission?
This information is found on the receipt form for each type of IRB submission. The number of copies required is listed in the right-most columns after a document name:
illustration of the new irb submission receipt

[back to top]

Contacting the IRB
Phone: (212) 263-4110
Fax: (212) 263-4147
eMail - general questions: irb-info@med.nyu.edu
eMail - questions for a study that has already been submitted (submit questions to the board your study was assigned to; include your study's IRB# in all communication): irb-board-a@med.nyu.edu irb-board-b@med.nyu.edu
newsletter feedback irb-feedback@med.nyu.edu
Recently Changed Forms
The IRB generally requires that you only submit the latest version of our forms. For this reason, we ask that you go to our website each time to download the form you need, as it may have recently changed.
  • Request for Initial IRB Review - September 28, 2006
  • Request for Initial IRB + GCRC Review - September 28, 2006
  • Submission Receipt (New) - August 1, 2006

  • [back to top]